Complete regression of xenografted human carcinomas by camptothecin analogue-carboxymethyl dextran conjugate (T-0128)

Cancer Research

Volumn 60, Issue 11, 2000, Pages 2988-2998

  Okuno, Satoshi ^a   Harada, Mitsunori ^b,c   Yano, Toshiro ^a   Yano, Shigeru ^a   Kiuchi, Satoko ^a   Tsuda, Naoki ^a   Sakamura, Yumi ^b   Imai, Jun ^b   Kawaguchi, Takayuki ^a   Tsujihara, Kenji ^a  

^a Discovery Research Laboratory   (Japan)

^b Discovery Research Laboratory   (Japan)

^c MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN DERIVATIVE; DEXTRAN DERIVATIVE; IRINOTECAN; T 0128; T 2513; TOPOTECAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER REGRESSION; CARCINOMA; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG RELEASE; DRUG TISSUE LEVEL; DRUG TUMOR LEVEL; FEMALE; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BREAST NEOPLASMS; CAMPTOTHECIN; CELL CYCLE; CHROMATOGRAPHY, GEL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEXTRANS; DNA TOPOISOMERASES, TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HELA CELLS; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PRODRUGS; RATS; RATS, WISTAR; TIME FACTORS; TISSUE DISTRIBUTION; TOPOTECAN; TUMOR CELLS, CULTURED;

EID: 0034212633     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Slichenmyer, W. J., Rowinsky, E. K., Donehower, R. C., and Kaufmann, S. H. The current status of camptothecin analogues as antitumor agents. J. Natl. Cancer Inst., 85: 271-291, 1993.
2. Cersosimo, R. J. Irinotecan: a new antineoplastic agent for the management of colorectal cancer. Ann. Pharmacother., 32: 1324-1333, 1998.
3. Cersosimo, R. J. Topotecan: a new topoisomerase I inhibiting antineoplastic agent. Ann. Pharmacother., 32: 1334-1343, 1998.
4. Chabot, G. G. Clinical pharmacokinetics of irinotecan. Drug Disp., 33: 245-259, 1997.
5. Takimoto, C. H., Wright J., and Arbuck S. G. Clinical applications of the camptothecins, Biochim. Biophys. Acta, 1400: 107-119, 1998.
6. Takakura, Y., and Hashida, M. Macromolecular drug carrier systems in cancer chemotherapy: macromolecular prodrugs. Crit. Rev. Oncol. Hematol., 18: 207-231, 1994.
7. Putnam, D., and Kopecek, J. Polymer conjugates with anticancer activity. Adv. Polym. Sci, 122: 55-123, 1995.
8. Vasey, P. A., Kaye, S. B., Morrison, R., Twelves, C., Wilson, P., Duncan, R., Thomson, A. H., Murray, L. S., Hilditch, T. E., Murray, T., Burtles, S., Fraier, D., Frigerio, E., and Cassidy, J. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents - Drug-polymer conjugates. Clin. Cancer Res., 5: 83-94, 1999.
9. Matsumura, Y., and Maeda, H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res., 46: 6387-6392, 1986.
10. Hertzberg, R. P., Caranfa, M. J., Holden, K. G., Jakes, D. R., Gallagher, G., Mattern. M. R. Mong, S-M., O'Leary Bartus, J., Johnson, R. K., and Kingsbury, W. D. Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J. Med. Chem., 32: 715-720, 1989.
11. Hashida, M., and Takakura, Y. Pharmacokinetics in design of polymeric drug delivery systems. J. Controlled Release, 31: 163-171, 1994.
12. Takakura, Y., and Hashida, M. Macromolecular carrier systems for targeted drug delivery: pharmacokinetic considerations on biodistribution. Pharm. Res., 6: 820-831, 1996.
13. Larsen, C. Dextran prodrugs-structure and stability in relation to therapeutic activity. Adv. Drug Delivery Rev., 3: 103-154, 1989.
14. Tsujihara, K., Kawaguchi, T., Okuno, S., and Yano T. Camptothecin derivatives. United States Patent 5,837,673, 1995.
15. Podzimek, S. The use of GPC coupled with a multiangle laser light scattering photometer for the characterization of polymers. On the determination of molecular weight, size, and branching. J. Appl. Polym. Sci, 54: 91-103, 1994.
16. Kawato, Y., Aonuma, M., Hirota, Y., Kuga, H., and Sato, K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res., 51: 4187-4191, 1991.
17. Nogusa, H., Yano, T., Kajiki, M., Gonsho, A., Hamana, H., and Okuno, S. Antitumor effects and toxicities of carboxymethylpullulan-peptide-doxorubicin conjugates. Biol. Pharm. Bull., 20: 1061-1065, 1997.
18. Trail, P. A., Willner, D., Lasch, S. J., Henderson, A. J., Hofstead, S., Casazza, A. M., Firestone, R. A., Hellström. I., and Hellström, K. E. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science (Washington DC), 261: 212-215, 1993.
19. Nakai, D., Fuse, E., Suzuki, H., Inaba, M., and Sugiyama, Y. Evaluation of the efficiency of targeting of antitumor drugs: simulation analysis based on pharmacokinetic/pharmacodynamic considerations. J. Drug Target., 3: 443-453, 1996.
20. Gerrits, C. J. H., de Jonge, M. J. A., Schellens, J. H. M., Stoter, G., and Verwcij, J. Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development. Br. J. Cancer. 76: 952-962, 1997.
21. Fassberg, J., and Stella, V. J. A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J. Pharm. Sci, 81: 676-684, 1992.
22. Gabr, A., Kuin, A., Aalders, M., El-Gawly, H., and Smets, L. A. Cellular pharmacokinetics and cytotoxicity of camptothecin and topotecan at normal and acidic pH. Cancer Res., 57: 4811-4816, 1997.
23. Chu, X-Y., Kato, Y., Ueda, K., Suzuki, H., Niinuma, K., Tyson, C., A., Weizer, V., Dabbs, J. E., Froehlich, R., Green, C. E., and Sugiyama, Y. Biliary excretion mechanism of CPT-11 and its metabolites in humans: involvement of primary active transporters. Cancer Res., 58: 5137-5143, 1998.